Table 1.
Reduction in tumor vascular permeability after anti-VEGF/VPF treatment: U87 tumors in cranial windows
| Control | Antibody-treated | Conditions |
|---|---|---|
| 1.00 (0.61–1.65) | 1.24 (0.58–1.62) | Two boluses of anti-VEGF antibody (N = 6) or PBS (N = 7) were injected i.p. at 0 and 4 h, and the tumor microvascular permeability was measured at 8 h |
| 1.33 (0.92–2.09) | 0.92 (0.40–1.59) | A bolus of anti-VEGF antibody (N = 4) or PBS (N = 4) was injected i.p., and the tumor microvascular permeability was measured at 2 days posttreatment |
| 2.85 (2.30–3.71) | 0.91 (0.51–2.06)* | A bolus of anti-VEGF antibody (N = 4) or PBS (N = 4) was injected i.p., and the tumor microvascular permeability was measured at 4 days posttreatment |
| 1.62 (1.50–2.07) | 0.73 (0.62–1.05)* | The anti-VEGF antibody (N = 4) or PBS (N = 4) was injected i.p. on days 7, 10, 14, and 17 after tumor tissue transplantation, and the tumor microvascular permeability was measured on day 18 |
The permeability data (10−7 cm/s) are shown as median (range). The antibody (492 μg/ml) or PBS was administered 7–23 days after tumor transplantation, depending on growth rate and vascularization of tumors. The dose of each injection was 0.2 ml.
*
P < 0.05 vs the matched control.